DRs C BARucHA and J C MCMILLAN (Belfast City Hospital, Belfast BT9 7AD) write: The use of intravenous immunoglobulin in high doses has become an accepted treatment for patients with autoimmune thrombocytopenia. The intravenous polyvalent pH 4 treated intact gammaglobulin concentrate prepared by the Swiss Red Cross (Sandoglobulin) has been evaluated in the laboratory,' and only a few minor adverse reactions have been reported in clinical trials2 3; the Committee on Safety of Medicines has received no reports ofadverse reactions. We report the occurrence ofsevere extensive eczema after infusion of Sandoglobulin.
The patient was a 75 year old woman who fulfilled the criteria for idiopathic thrombocytopenic purpura when thrombocytopenia was first noted in 1982. After initially responding to steroids she became refractory, and Sandoglobulin infusions (1 g/kg daily for two days) were started in April 1986. No adverse reactions were noted, and her platelet count rose from 6x 109/1 to 158 x 109/1. She received a second infusion of Sandoglobulin seven weeks later, but at review one month after the infusion she complained of a rash, which had appeared one week previously and had been diagnosed by her general practitioner as "allergic." She was successfully treated with topical steroids and oral antihistamine. There was no history of atopy. She received a third course of Sandoglobulin after another interval of six weeks, and at review two weeks after the infusion she had a florid generalised eczematous rash. The clinical appearance was consistent with acute excoriated eczema, and a skin biopsy specimen suggested a drug reaction.
Cutaneous reactions like angio-oedema, urticaria, and pruritus are associated with blood products, while eczematous reactions are rare. Cutaneous reactions after infusion of hydroxyethyl starch have been reported.4 The manufacturers of Sandoglobulin have received one report ofa case from the United States, in which sensitisation to porcine pepsin (1:10000 to prevent aggregates) was suspected to be due to previous exposure to insulin (E M Thompson, personal communication) . Despite extensive studies we found no proof of a humoral or cellular mechanism. Our patient has required several additional infusions of Sandoglobulin, which were given with concommitant administration of hydrocortisone and chlorpheniramine together with topical steroid applications. There has been no acute exacerbation with each infusion, although she continues to suffer from widespread eczema. A 65 year old woman had been receiving anticoagulant treatment with warfarin for 11 years since an aortic valve replacement; the total weekly dose had varied between 27 mg and 28 5 mg, producing a prothrombin time of 23 to 34 seconds (control 12 seconds). In October 1986 she had had a mastectomy for breast carcinoma. Histology showed an infiltrating duct carcinoma with no affected nodes. There was no evidence at this time, or subsequently, of metastatic disease. Treatment with tamoxifen 10 mg twice daily was started on 5 October 1986; her warfarin dose remained unchanged. When she was discharged from hospital on 8 October her prothrombin time was 39 seconds (control 14 seconds). Three weeks later, in an anticoagulant clinic elsewhere, her prothrombin time was found to be 75 6 seconds (control 14 seconds). This was assumed to be due to a five day course of cotrimoxazole that she was taking for a respiratory infection, and the dose of warfarin was left unchanged. On 21 November, six weeks after she was discharged from hospital, she was readmitted with a three day history of haematemesis, abdominal pain, and haematuria. Her prothrombin time was found to be 206 seconds (control 14 seconds). She gave no history of ingestion of any other drugs, and there was no evidence of metastatic disease. Renal and hepatic function, as assessed by conventional biochemical tests, was normal. She was treated with fresh frozen plasma, and anticoagulant treatment was withdrawn until her prothrombin time had returned to within the therapeutic range. The haematuria ceased within 12 hours of admission, and she had no further haematemesis; upper gastrointestinal endoscopy yielded normal results. Treatment with warfarin was restarted on the fifth day after admission, and when she was discharged her weekly warfarin dosage had fallen to 17-5 mg and her prothrombin time was stable at 34 to 37 seconds (control 14 seconds). She continued to take tamoxifen throughout this time.
There seems no doubt that treatment with tamoxifen led to this patient's overanticoagulation. This is surprising because there have been reports of venous and arterial thrombosis associated with tamoxifen.' There has been one report to the manufacturer (ICI), however, of a patient whose prothrombin time increased from 20-22 seconds to 50-60 seconds one month after treatment with tamoxifen was started. This patient was also taking phenobarbitone and phenytoin. The mechanism of the interaction is unclear, but inhibition of warfarin metabolism is a possibility. Inhibition ofthe cytochrome P450 enzyme system by tamoxifen has been shown in animals.2 Increased digitoxin concentrations after administration of tamoxifen have also been reported,3 and digitoxin is probably metabolised by the same enzyme system as warfarin. Alternatively, oestrogens increase concentrations of clotting factors and, therefore, theoretically an antioestrogen might reduce them. Tamoxifen may produce an acquired factor VIII deficiency,4 but there was no evidence of this in our patient. A 71 year old man received two courses of intramuscular gentamicin for perineal infection, lasting eight days and six days, both at a dose of 80 mg three times a day. During the second course he complained of nausea and dizziness. Serum gentamicin concentration was 13-6 mg/I, and the drug was discontinued. He was also taking frusemide 80 mg day orally, metronidazole, ampicillin, dihydrocodeine, and temazepam. On becoming mobile after his illness he noted difficulty in maintaining his balance in the dark. He experienced abnormal sensations of motion while in bed and had bobbing oscillopsia while walking. He had no hearing loss, tinnitus, or vertigo. Neurological examination showed no impairment of posterior column sensation or of coordination of the arms. On closing his eyes he had complete ataxia of trunk and legs and could neither sit nor stand upright. There was no positional vertigo or nystagmus and no response to maximal caloric stimulation in either ear. Audiometry was normal. A magnetic resonance imaging scan showed minimal cerebellar atrophy. Closing the eyes removes one of the three inputs to postural control. If posteriorcolumn sensation is also absent the remaining input from the vestibular apparatus is insufficient, and the patient will fall. Presumably the same applies when vestibular function is absent and only posterior column sensation remains. Why then is rombergism not a more common result of gentamicin toxicity? While it is preferentially vestibulotoxic, and tends to leave cochlear function intact,2 gentamicin may be even more specifically toxic to the semicircular canals, leaving otolith function relatively intact.3 Since output from the otolith organs is mainly tonic, there remains a vestibular input to postural control with the head static, allowing maintenance of posture with the eyes closed. This case illustrates that gentamicin toxicity may present with rombergism with no hearing loss and no overt features of vestibular dysfunction. 
